Drug Trial Radar · NCT02847598
Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)
Last checked: Nov 19, 2026Latest source record: Nov 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
264
Actual
Start
Oct 20, 2016
Primary completion
Aug 28, 2019
Study completion Nov 18, 2019
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Jul 28, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of the study is to evaluate the efficacy of BIIB059 (litifilimab) in reducing disease activity in participants with systemic lupus erythematosus (SLE) with active cutaneous manifestations and joint involvement (Part A), and in participants with active cutaneous lupus erythematosus (CLE) (Subacute cutaneous lupus erythematosus (SCLE) or chronic CLE, including discoid lupus erythematosus (DLE)) with or without systemic manifestations (Part B). The secondary objective is to evaluate additional efficacy parameters of BIIB059 in reducing SLE/CLE disease activity, pharmacokinetic parameters, safety and tolerability of BIIB059 (Parts A and B).
Conditions
- Systemic Lupus Erythematosus
- Active Cutaneous Lupus Erythematosus
Interventions
BIIB059 (litifilimab)Drug
Administered as specified in the treatment arm.
PlaceboDrug
Administered as specified in the treatment arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Change From Baseline in Active Joint Count (28-joint Assessment) to Week 24Time frame: Baseline to Week 24
- Part B: Percent Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) Score to Week 16Time frame: Baseline to Week 16
Locations
128 sites in 12 countries. Site status is shown where the registry gives one.
Pinnacle Research Group LLC
Anniston, Alabama
Arizona Arthritis & Rheumatology
Phoenix, Arizona
University of Arkansas for Medical Sciences
Little Rock, Arkansas
TriWest Research Associates, LLC
El Cajon, California
Tien Q Nguyen MD Inc
Fountain Valley, California
MD Med Corp
Hemet, California
Universtiy of California, Irvine
Irvine, California
The Regents of the University of California
La Jolla, California
Purushotham Akther & Rosan Kotha, MD Inc.
La Mesa, California
Dermatology Reserach Associates
Los Angeles, California
University Clinical Trials
San Diego, California
Richard Barthel, MD
Santa Barbara, California
Robin K. Dore, MD, Inc.
Tustin, California
Inland Rheumatology Clinical Trials Inc.
Upland, California
Nazanin Firooz, MD Inc.
West Hills, California
Denver Arthritis Clinic
Denver, Colorado
Medical Faculty Associates, Inc.
Washington D.C., District of Columbia
Howard University Hospital
Washington D.C., District of Columbia
Washington DC VA Medical Center
Washington D.C., District of Columbia
Clinical Research of West Florida- Corporate
Clearwater, Florida
Medical Research Center Of Miami
Miami, Florida
Lakes Research, LLC
Miami Lakes, Florida
Omega Research Consultants
Orlando, Florida
Compass Research, LLC
Orlando, Florida
DMI Research, Inc.
Pinellas Park, Florida
Advanced Medical Reserarch, PC
Sandy Springs, Georgia
Advanced Clinical Research
Boise, Idaho
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana
Brigham and Women's Hospital
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Washington University School of Medicine
St Louis, Missouri
Davis Group, LTD
Las Vegas, Nevada
Valley Hospital
Ridgewood, New Jersey
Institute for Rheumatic & Autoimmune diseases, Overlook Medical Center
Summit, New Jersey
Albuquerque Center For Rheumatology
Albuquerque, New Mexico
North Shore/Long Island Jewish PRIME
Great Neck, New York
Univeristy of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Joint and Muscle Research Institute
Charlotte, North Carolina
American Health Research, Inc.
Charlotte, North Carolina
Medication Management, LLC
Greensboro, North Carolina
Showing 40 of 128 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.